The Department of Diagnostic and Interventional Imaging, Nuclear Medicine section is proud to be one of the leaders in the nation in imaging the burden of beta-amyloid in the brain with the recently approved F-18 Amyvid scans.
F-18 Amyvid binds to beta-amyloid deposits in the brain, which are frequently found in patients with Alzheimer’s disease (AD). Amyvid PET scan is usually indicated in patients with cognitive dysfunction. A negative Amyvid PET scan excludes the diagnosis of AD as the reason for cognitive impairments. A positive Amyvid PET scan indicates moderate to marked amyloid plaque deposits, which occur in AD, other cognitive disorders, and even in normal older people. Thus, a positive Amyvid scan does not establish the diagnosis of AD but is performed as an adjunct to other diagnostic evaluations.
Dr. Isis Gayed, associate professor of radiology and chief of nuclear medicine, and Drs. David Wan and Usha Joseph, assistant professors of radiology, are pleased with the quality of the images and results of the first few patients who have undergone this new exciting imaging modality.
For inquires about this scan, please call the PET Center, 713.704.9046.